Ntoeng e khahlano le mofetše oa pancreatic, liteko tse ncha le tse ncha tsa bongaka li fetohile tse mahlonoko haholo. Liteko tsena li fa bakuli monyetla oa ho fumana liphekolo tsa maemo a holimo tse ka lebisang tsoelopeleng ea lipatlisiso le tšepo ea liphetho tse betere.
Kalafo e 'ngoe le e 'ngoe e teng kajeno e ile ea etsoa lipatlisiso, ea ntlafatsoa le ho amoheloa ka teko ea bongaka - thuto ea lipatlisiso e batlisisang liphekolo tse ncha kapa motsoako oa liphekolo tse teng ho fumana hore na li molemo ho batho ba phelang le kankere ea pancreatic. Kankere ea Pancreatic e ntse e tsoela pele ho ba ntho e tšoenyang lefats'e ka bophara, e ntse e tsoela pele ho tsamaisa tlhoko ea mahlale a kalafo le boiteko ba ntlafatso ea lithethefatsi. Litlhoko tse sa finyelloang tse amanang le lefu lena li hohela lik'hamphani tse ngata tsa machaba ho tsetela indastering. Lintlha tsena li kopantsoe le litšenyehelo tse ntseng li eketseha tsa tlhokomelo ea bophelo lefatšeng ka bophara li tla eketsa kholo ea 'maraka. Tlaleho e tsoang ho Global Market Insight e boletse hore boholo ba 'Maraka oa Kalafo ea Kankere ea Pancreatic bo lebelletsoe ho hlahisa chelete e ngata nakong ea 2021 ho isa 2027. Tlaleho e ile ea tsoela pele: "Kankere ea Pancreatic e nkuoa e le e' ngoe ea mefuta e mabifi ka ho fetisisa ea mofets'e e hlahang liseleng tsa pancreatic 'me e ka khona kapele. namela dithong tse haufi. Likhetho tse sa pheleng tsa bophelo tse kang ho tsuba, ho noa joala le koae hammoho le maloetse a amanang le mokhoa oa bophelo a kang botenya le lefu la tsoekere ke tse ling tsa lisosa tse ka sehloohong tsa kankere ea pancreatic. Mokhatlo oa Amerika oa Kankere o hakanya hore Maamerika a fetang 60,000 2021 a tla fumanoa a e-na le mofetše oa pancreatic ka XNUMX. Mekhoa e tšoanang e ntse e bonoa likarolong tse ling tse ngata tsa lefatše e leng se tla matlafatsa mekhoa ea indasteri.” Likhamphani tse sebetsang tsa biotech le pharma 'marakeng bekeng ena li kenyelletsa Oncolytics Biotech® Inc., Bristol Myers Squibb, Seagen Inc., Exact Sciences Corp., Kura Oncology, Inc.
Global Market Insight e ekelitse: "Chemotherapy, immunotherapy, kalafo e lebisitsoeng, le kalafo ea lihormone, har'a tse ling, ke mefuta e fapaneng ea likhetho tsa kalafo ea mofetše oa pancreatic. Har'a tsena, karolo ea kalafo e lebisitsoeng ho eona e kanna ea hapa karolo e nepahetseng ea mmaraka ka 2027. Phekolo e reriloeng e shebana le liprotheine tse khethehileng tsa mofetše, liphatsa tsa lefutso kapa lisele tse tlatsetsang kholong ea mofetše. Kalafo e thibela kholo le ho ata ha lisele tsa mofetše ha e ntse e fokotsa tšenyo ho tse phetseng hantle. Phekolo e reriloeng e tla bona tlhoko e ntseng e eketseha ea kalafo ea mofetše oa pancreatic lilemong tse tlang. ”
Oncolytics Biotech® e Fana ka Nchafatso e Ntle ea Tšireletso ho Sehlopha sa Kankere ea Pancreatic ea Multi-Indication Phase 1/2 Teko ea Kankere ea Kankere ea Kankere - Oncolytics Biotech® ) kajeno e phatlalalitse katleho e atlehileng ea ts'ireletso ea bakuli ba bararo bakeng sa sehlopha sa mofets'e oa pancreatic. mohato oa 1/2 thuto ea GOBLET e latelang tlhatlhobo e entsoeng ke Boto ea Boithuto ba Ts'ireletso ea Boitsebiso (DSMB). DSMB ha ea ka ea hlokomela mathata a polokeho ho bakuli bana mme e khothalelitse hore thuto e tsoele pele joalo ka ha ho reriloe. Ts'ireletseho ea ts'ireletso bakeng sa sehlopha sa liteko sa moleng oa boraro oa mofetše oa metastatic colorectal e ntse e tsoela pele.
Boithuto bona ba GOBLET bo laoloa ke AIO, sehlopha se etelletseng pele sa thuto ea bongaka sa oncology se thehiloeng Jeremane, 'me se etselitsoe ho lekola polokeho le katleho ea pelareorep hammoho le Roche's anti-PD-L1 checkpoint inhibitor atezolizumab ho bakuli ba nang le metastatic pancreatic, metastatic. colorectal, le kankere ea mahlahahlaha e tsoetseng pele. Boithuto bona bo ntse bo tsoela pele 'me ho lebelletsoe ho ngolisa bakuli libakeng tse 14 tsa liteko tsa bongaka ho pholletsa le Jeremane.
Sehlopha sa thuto ea GOBLET sa mofets'e oa mofets'e se atolosa lintlha tsa kliniki tse tlalehiloeng pele tse bonts'ang ts'ebetso e ts'oanang le e khahlanong le mofets'e ea pelareorep e kopantsoeng le thibelo ea tlhahlobo ho bakuli ba mofets'e oa pancreatic ba ileng ba hatela pele kamora kalafo ea pele (sehokelo ho PR, sehokelo ho poster). E boetse e hahela holim'a lintlha tsa pele tsa kliniki tse bontšitseng keketseho e fetang 80% ea ho pholoha ho se nang tsoelo-pele ea bohareng ho bakuli ba mofetše oa pancreatic ba nang le maemo a tlase a polelo ea CEACAM6 ba amohetseng pelareorep hammoho le chemotherapy (link ho PR, link to poster). Ntle le ho lekola polokeho le katleho ea kalafo ea pelareorep-atezolizumab, GOBLET e boetse e batla ho bonts'a bokhoni ba CEACAM6 le T cell clonality e le li-biomarker tse boletsoeng esale pele, tse ka eketsang monyetla oa katleho ea lithuto tsa ngoliso tsa nako e tlang ka ho lumella khetho ea bakuli ba loketseng ka ho fetisisa. .
Seagen Inc. haufinyane e phatlalalitse lintlha tse tsoang tekong ea kliniki ea mohato oa 1 e kopanyang SEA-CD40 le chemotherapy le anti-PD-1 ho bakuli ba nang le metastatic PDAC kopanong ea selemo le selemo ea ASCO GI e neng e tšoaretsoe San Francisco, January 20 - 22, 2022. SEA -CD40 ke novel, researchal, nonfucosylated monoclonal receptor-agonistic antibody e lebisitsoeng ho CD40, e hlahisoang ka lisele tse hlahisang antigen. Mehlala ea pele, ho kopanngoa ha SEA-CD40 le chemotherapy ho felletse ka ts'ebetso ea antitumor e matlafatsoa le ho feta ka kalafo ea anti-PD-1.
Tekong e tsoelang pele ea mohato oa 1, SEA-CD40 e kopantsoe le chemotherapy [gemcitabine le nab-paclitaxel (GnP)], le anti-PD-1 (pembrolizumab), ho bakuli ba 61 ba nang le metastatic PDAC e sa phekoloeng. Har'a bona, bakuli ba 40 ba fumane 10 mcg / kg 'me bakuli ba 21 ba fumane 30 mcg / kg ea SEA-CD40. Lintlha tsa bohlokoa li kenyelletsa sekhahla sa karabelo ea sepheo se tiisitsoeng (cORR) ka RECIST v1.1 ke mofuputsi, ho pholoha ntle le tsoelo-pele (PFS) le pholoho ka kakaretso (OS) "Mosebetsi oa pele oa khothatsa ho latela liphello tsa histori tsa chemotherapy. Ho hlokahala tlhahlobo e eketsehileng ea ho pholoha ho tsebisa mehato ea rona e latelang ea mofetše oa pancreatic, "ho boletse Roger Dansey, MD, Ofisiri e ka Sehloohong ea Bongaka Seagen. "Re ntse re tsoela pele ho ntšetsa pele teko e ntseng e tsoela pele ea mohato oa 2 oa SEA-CD40 ho melanoma le mofetše o seng o monyane oa lisele tsa matšoafo."
Haufinyane tjena, Exact Sciences Corp e phatlalalitse lintlha tsa ts'ebetso bakeng sa tlhahlobo ea Cologuard ea moloko oa bobeli (DNA e nang le sepheo se sengata) e bontšang kutloisiso e akaretsang ea 95.2% bakeng sa kankere ea mala (CRC) ka ho khetheha 92.4% bakeng sa lisampole tse mpe tse tiisitsoeng ke colonoscopy. Litlhahlobo tsa sehlopha se senyenyane li bonts'itse 83.3% ea kutlo bakeng sa dysplasia ea boemo bo holimo, liso tse kotsi ka ho fetisisa tsa mofets'e, le 57.2% bakeng sa maqeba ohle a tsoetseng pele a precancerous. Lintlha tsena li tla hlahisoa ka la 22 Pherekhong ho ASCO GI posong e nang le sehlooho se reng, "Moloko oa Bobeli oa Multi-Target Stool DNA Panel e Fumana Mofets'e oa Colourectal le Les Advanced Precancerous Lesions."
Cologuard ke teko ea pele le e le 'ngoe feela e amohetsoeng ke FDA, e sa hlaselehang habonolo ea DNA e sebelisoang ho lekola batho ba kotsing ea kakaretso bakeng sa CRC. Exact Sciences e nts'etsapele mofuta oa bobeli oa Cologuard ho ntlafatsa ho nepahala le kutloisiso ea tlhahlobo ea mofetše, ho fokotsa sekhahla se fosahetseng le ho eketsa sekhahla sa ho lemoha maqeba a precancerous. Boithuto bona bo bonts'a bokhoni ba phanele e khethollang haholo ea li-marker tsa methylated DNA le fecal hemoglobin ho fihlela ka bobeli maemong a nnete a lefats'e. Haeba e amohetsoe, tlhahlobo ea Cologuard ea moloko oa bobeli e ka thusa ho eketsa litekanyetso tsa tlhahlobo ha e ntse e romela batho ba fokolang ho latela li-colonoscopies ho sa hlokahale le ho tsebahatsa li-precancers tse tsoetseng pele pele li fetela mofetšeng, ho thusa ho thibela lefu lena.
Bristol Myers Squibb haufinyane o phatlalalitse Komiti ea Meriana ea Meriana bakeng sa Tšebeliso ea Batho (CHMP) ea European Medicines Agency (EMA) e khothalelitse tumello ea Breyanzi (lisocabtagene maraleucel; liso-cel), CD19-directed chimeric antigen receptor (CAR) T cell. Kalafo bakeng sa phekolo ea bakuli ba baholo ba nang le ho khutlela morao kapa ho hanyetsa (R / R) ho jala B-cell lymphoma e kholo (DLBCL), mediastinal e kholo ea B-cell lymphoma (PMBCL), le follicular lymphoma grade 3B (FL3B) ka mor'a mela e 'meli kapa ho feta ea tsamaiso ea phekolo. Khomishene ya CHMP jwale e tla hlahlojwa ke Khomishene ya Yuropa (EC), e nang le matla a ho fana ka tumello ya meriana bakeng sa European Union (EU).
Kura Oncology, Inc., k'hamphani ea biopharmaceutical ea boemo ba bongaka e ikemiselitseng ho phethahatsa tšepiso ea meriana e nepahetseng bakeng sa kalafo ea mofets'e, haufinyane e phatlalalitse hore Tsamaiso ea Lijo le Lithethefatsi ea US (FDA) e phahamisitse ts'ebetso e itseng ea bongaka molemong oa KOMET-001 Phase. Thuto ea 1b ea KO-539 ho bakuli ba nang le lefu la ho khutlela morao kapa la refractory acute myeloid leukemia (AML). Boemo bo sa fellang ba kliniki bo ile ba phahamisoa ka mor'a tumellano le FDA mabapi le leano la Khampani la phokotso ea lefu la phapang, e leng ketsahalo e mpe e tsebahalang e amanang le ho arola liakhente kalafong ea AML.
